Zhengye Biotechnology Holding Limited Adopts Dual-Class Share Structure

(SeaPRwire) –   Jilin, China, April 06, 2026 — Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine producer covering research, development, manufacturing, and sales of veterinary vaccines—with a focus on livestock vaccines in China—today announced the adoption of a dual-class share structure, taking effect on April 7, 2026.

During the annual general meeting of shareholders held on March 24, 2026, the Company’s shareholders approved the introduction of two types of ordinary shares, labeled Class A and Class B. The Company’s Class A ordinary shares are set to start trading on the Nasdaq Capital Market when markets open on April 7, 2026, retaining the ticker symbol “ZYBT.” While the CUSIP number will remain unchanged, the CUSIP description will be updated to reflect the new classification as Class A ordinary shares.

Under the dual-class share structure, the Company’s authorized share capital of US$50,000 is reclassified and re-designated into 2 billion ordinary shares, each with a par value of US$0.000025. These consist of (i) 1.9 billion Class A ordinary shares (each with a par value of US$0.000025) and (ii) 100 million Class B ordinary shares (each with a par value of US$0.000025). Each Class A ordinary share carries one vote, while each Class B ordinary share entitles the holder to 20 votes on all matters subject to voting at the Company’s general meetings. Any Class B ordinary share can be converted into one Class A ordinary share at any time at the holder’s discretion, but Class A ordinary shares can never be converted into Class B ordinary shares.

To reflect the share capital restructuring, Zhengye has adopted revised and restated memorandum and articles of association, which have been properly filed and are now in effect.

About Zhengye Biotechnology Holding Limited

Via Jilin Zhengye Biological Products Co., Ltd.—its operational subsidiary based in Jilin, China—Zhengye Biotechnology Holding Limited focuses on the research, development, production, and sale of veterinary vaccines, with a particular emphasis on livestock vaccines. For over 20 years, this operational entity has been committed to improving animal health. It offers 50 veterinary vaccines, including those for swine, cattle, goats, sheep, poultry, and dogs. Its products are available in 28 provincial regions across China and are exported to Vietnam, Pakistan, and Egypt. The operational entity has three GMP-compliant veterinary vaccine production facilities (including 13 GMP production lines), a quality testing center, and an animal facility for vaccine development. It employs 49 staff members with over a decade of tenure and experience in the veterinary vaccine industry. For more information, please visit the Company’s website: http://ir.jlzybio.com.

Forward-Looking Statements

This announcement contains statements that may qualify as “forward-looking” statements, made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve both known and unknown risks and uncertainties, and are based on the Company’s current expectations and projections of future events it believes may impact its financial condition, operational results, business strategy, and financial needs. Investors can identify many (though not all) of these statements through terms like “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or other similar expressions in this announcement. Statements that are not historical facts—including those about the Company’s beliefs, plans, and expectations—are forward-looking statements. Forward-looking statements carry inherent risks and uncertainties. The Company has no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or changes in expectations, except as required by law. While the Company believes the expectations in these forward-looking statements are reasonable, it cannot guarantee they will prove correct. The Company cautions investors that actual results may differ materially from anticipated outcomes and encourages them to review other factors affecting future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For further information, please contact:

Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com